Evelyn Verbeke

Evelyn Verbeke

Auto-generated profile, based on publicly available information

Evelyn Verbeke

Department of Public Health and Primary Care Leuven Institute for Healthcare Policy, KU Leuven Leuven Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Birth
Verified
Journal Article
Closed access
EVEvelyn Verbeke
Evelyn Verbeke
ABAnnick Bogaerts
Annick Bogaerts
TNTinne Nuyts
Tinne Nuyts
NCNeeltje Crombag
Neeltje Crombag
ALAcco Luyten
Acco Luyten

7 November 2021 in Health Economics
Verified
Journal Article
Closed access
PDF file
ALAcco Luyten
Acco Luyten
EVEvelyn Verbeke
Evelyn Verbeke
ESErik Schokkaert
Erik Schokkaert

2 February 2022 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Open access
ALAcco Luyten
Acco Luyten
MCMark Connolly
Mark Connolly
EVEvelyn Verbeke
Evelyn Verbeke
KBKlaus Buhler
Klaus Buhler
GSGraham Scotland
Graham Scotland
TDThomas D'Hooghe
Thomas D'Hooghe
Economic evaluations of the value-for-money of Medically Assisted Reproduction (MAR) interventions are increasingly important due to growing pressure on healthcare budgets. Although such evaluations are commonplace in the published literature, the number/methodological complexity of different evaluations available, and the challenges specific to MAR interventions, can complicate the interpretation of such analyses for fertility treatments. This article aims to serve as an educational resource and provide context on the design/interpretation of economic analyses for MAR interventions. Several areas are relevant for first-line providers and decision makers: scope of analysis, comparator used, perspective/time horizon considered, outcomes used to measure success, and how results from cost-effectiveness studies can be summarised and used in clinical practice. We aim to help clinicians better understand the strengths/weaknesses of economic analyses, to enable the best use of the evidence in practice, so resources available for MAR interventions can provide maximum value to patients and society.

29 October 2021 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
EVEvelyn Verbeke
Evelyn Verbeke
ALAcco Luyten
Acco Luyten
Economic evaluation guidelines increasingly prescribe inclusion of all future costs. We point at an important dimension of future costs that is systematically neglected. Healthcare can affect future offspring, either through affecting the patient’s fertility or through determining future offspring’s health. As we show, the future costs associated with these changes can be substantial and will vary across interventions and demographic groups. However, systematic inclusion of these future offspring costs would raise many problems on its own. Based on the population ethics concept of necessitarianism, we suggest that only those future costs that spring from ‘necessary’ future lives should be included in future cost calculations, while all costs associated with ‘potential’ future lives can be ignored. This approach allows excluding most future offspring costs and avoids skewed cost-effectiveness outcomes of interventions with fertility effects, while taking into account the economic implications of preventing disease in future generations that will exist by necessity. Overall, future generations expose a substantial gap in today’s Health Technology Assessment (HTA) methodology and further discussion of the issues they raise is needed.